Snapshot · McKesson Corporation (MCK)

Data as of 2026-10-19T08:14:31.180Z

Fundamentals check

Market cap

$117.2B

P/E (TTM)

26.8

Gross margin

3.6%

Net margin

1.1%

ROE

-194.4%

R&D / revenue

0.0%

Dividend yield

0.3%

FCF yield

5.3%

Latest dividend: $0.94/share (ex-date 2026-09-01, quarterly)

Summary

McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.

How it makes money

Revenue mix, latest fiscal year

• North American Pharmaceutical Segment83.4%
• Oncology And Multispecialty Segment12%
• Medical-Surgical Solutions Segment2.9%
• Prescription Technology Solutions Segment1.4%
• Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment0.3%

Recent Events

• 2026-10-15T04:42:47.000Zpositive

  691 Shares in McKesson Corporation $MCK Bought by Sax Wealth Advisors LLC

  恰逢机构增持消息，可能与市场情绪变化相关，但不构成因果关系。

  Source: defenseworld.net

• 2026-10-15T03:56:57.000Zpositive

  McKesson Corporation $MCK Stock: First Citizens Bank & Trust Co. Increases Stake

  恰逢机构增持，可能对投资者情绪有积极作用，未必直接推动因果。

  Source: defenseworld.net

• 2026-10-14T21:00:03.000Zneutral

  McKesson (MCK) Ascends While Market Falls: Some Facts to Note

  分析报道指出股价相对市场的表现，可能与市场环境相关，但不证明因果。

  Source: Zacks Investment Research

• 2026-10-01T00:00:00.000Zpositive

  Price move: MCK rose 5.3%

  MCK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-09-14T00:00:00.000Zpositive

  Price move: MCK rose 3.3%

  MCK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-25T00:00:00.000Zpositive

  Price move: MCK rose 3.6%

  MCK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-05T00:00:00.000Zneutral

  MCK filed 10-Q

  可能与最新财报披露相关，但不能确定对股价的直接因果关系。

  Source: SEC EDGAR

• 2026-08-05T00:00:00.000Zpositive

  Price move: MCK rose 5.6%

  MCK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-07-28T00:00:00.000Zpositive

  Price move: MCK rose 4.6%

  MCK 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $995 from 6 analysts (last quarter)

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-09-08SellRutledge Napoleon B JR(officer: SVP, Controller & CAO)111 shares
• 2026-08-10SellLerman Bradley E(director)301 shares

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。